

Exceptional outcomes. *Proven again.*

SuperB Study results: Quality of life (QOL) benefits in complex SFA lesions.

100%

Limb salvage in long, complex SFA lesions (n = 63)¹

- 23.3 cm average lesion length
- 38.1% critical limb ischemia (CLI)
- 96.7% TASC II C&D lesions



Improvement in 1-month patient outcomes

Multicenter, randomized controlled trial comparing GORE® VIABAHN® Endoprosthesis to Femoropopliteal Bypass¹

	GORE® VIABAHN® ENDOPROSTHESIS (n = 63)	SURGICAL BYPASS (n = 62)*	P VALUE
Improvement in patient outcomes			
Hospitalization time	3.7 days	6.0 days	P = 0.002
QOL (SF-36, 1 month)	50.2%	37.1%	P = 0.011
Walking impairment questionnaire (1 month)	68.5%	47.6%	P < 0.05
Total complications (1 month)	25	61	P = 0.048
No difference in 12-month patencies or reinterventions			
Primary	64.8%	63.6%	—
Secondary	85.9%	83.3%	—
Freedom from CD-TLR	77.0%	70.0%	—

* 67.7% Vein; 32.3% Prosthetic graft.



Proven patency for complex SFA lesions.

422 Limbs Studied

302 CTOs

22cm Average Lesion Length*

75% Average Primary Patency**



STUDY	NUMBER OF LIMBS	LESION LENGTH (cm)	CTOs (%)	12-MONTH PRIMARY PATENCY (%)	12-MONTH SECONDARY PATENCY (%)
SuperB ¹	63	23	75	65	78
Gore VIPER Clinical Study ²	119	19	56	73	92
VIASTAR Trial ³	66	19	79	78	90
25 cm Trial ⁴	71	27	93	67	97
Japan IDE Clinical Study ⁵	103	22	66	88	98
Combined results (weighted average, as appropriate)	422	22	70	75	92

Read the SuperB Study Abstract at goremedical.com/viabahn/superb.

* Weighted average lesion length.

** 12-Month weighted average primary patency.

1. Reijnen MMPJ, van Walraven LA, Fritschy WM, *et al.* 1-year results of a multicenter randomized controlled trial comparing heparin-bonded endoluminal to femoropopliteal bypass. *JACC: Cardiovascular Interventions* 2017;10(22):2320-2331.
2. Saxon RR, Chervu A, Jones PA, *et al.* Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) Trial. *Journal of Vascular & Interventional Radiology* 2013;24(2):165-173.
3. Lammer J, Zeller T, Hausegger KA, *et al.* Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). *Journal of the American College of Cardiology* 2013;62(15):1320-1327.
4. Zeller T, Peeters P, Bosiers M, *et al.* Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm Trial. *Journal of Endovascular Therapy* 2014;21(6):765-774.
5. Ohki T, Kichikawa K, Yokoi H, *et al.* Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions. *Journal of Vascular Surgery* 2017;66(1):130-142.e1.



W. L. GORE & ASSOCIATES, INC.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)
00800.6334.4673 (Europe)
800.437.8181 (United States)
928.779.2771 (United States)

goremedical.com



Consult Instructions for Use

Products listed may not be available in all markets.

GORE®, VIABAHN®, and designs are trademarks of W. L. Gore & Associates.
© 2018 W. L. Gore & Associates, Inc. AX0519-EN1 MAY 2018